


AMENDMENTS TO THE CLAIMS

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application. Please amend the claims as follows.

1. (Currently Amended) A compound of Formula (I):



wherein

a and b are equal to 0 and 1; wherein the values of 0 and 1 are a direct bond and $-\text{CH}_2-$, respectively, and wherein the $-\text{CH}_2-$ group is optionally substituted 1 to 2 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups: -alkyl, -aryl, -alkylene-aryl, -arylene-alkyl, -alkylene-arylene-alkyl, -O-alkyl, -O-aryl, or -hydroxyl;

W is $-\text{N}(\text{R}_4)-$;

wherein

R_4 is

- a) -hydrogen;
- b) -alkyl;
- c) $-\text{L}_2\text{-D-G}$;
- d) $-\text{L}_2\text{-D-alkyl}$;
- e) $-\text{L}_2\text{-D-aryl}$;
- f) $-\text{L}_2\text{-D-heteroaryl}$;
- g) $-\text{L}_2\text{-D-cycloalkyl}$;
- h) $-\text{L}_2\text{-D-heterocyclyl}$;
- i) $-\text{L}_2\text{-D-arylene-alkyl}$;

- j) – L₂-D-alkylene-cycloalkyl;
- k) – L₂-D-alkylene-heterocyclyl;
- l) – L₂-D-alkylene-aryl;
- m) – L₂-D-alkylene-heteroaryl;
- n) – L₂-D-alkylene-arylene-alkyl;
- o) – L₂-D-alkylene-heteroarylene-alkyl;
- p) – L₂-D-alkyl-G;
- q) – L₂-D-aryl-G;
- r) – L₂-D-heteroaryl-G;
- s) – L₂-D-cycloalkyl-G;
- t) – L₂-D-heterocyclyl-G;
- u) – L₂-D-arylene-alkyl-G;
- v) – L₂-D-alkylene-cycloalkyl-G;
- w) – L₂-D-alkylene-heterocyclyl-G;
- x) – L₂-D-alkylene-aryl-G;
- y) – L₂-D-alkylene-heteroaryl-G;
- z) – L₂-D-alkylene-arylene-alkyl-G; or
- aa) – L₂-D-alkylene-heteroarylene-alkyl-G;

wherein


L₂ is a direct bond, –alkylene, –alkenylene, or –alkynylene;

D is a direct bond, –CH₂–, –O–, –N(R₅)–, –C(O)–, –CON(R₅)–, –N(R₆)C(O)–, –N(R₆)CON(R₅)–, –N(R₅)C(O)O–, –OC(O)N(R₅)–, –N(R₅)SO₂–, –SO₂N(R₅)–, –C(O)–O–, –O–C(O)–, –S–, –S(O)–, –S(O₂)–, or –N(R₅)SO₂N(R₆)–, –N=N–, or –N(R₅)–N(R₆)–,

wherein R₅ and R₆ are independently selected from the group

consisting of : –hydrogen, –alkyl, –aryl, –arylene-alkyl, –alkylene-aryl, and –alkylene-arylene-alkyl;

G is –H, –alkyl, –CN, –SO₃H, –P(O)(OH)₂, –P(O)(O-alkyl)(OH), –CO₂H, –CO₂-alkyl, an acid isostere, –NR₇R₈,



wherein

L₁₀ is alkylene, cycloalkylene, heteroarylene, arylene, or heterocyclylene;

L₁₂ is -O-, -C(O)-N(R₄₀)-, -C(O)-O-, -C(O)-, or -N(R₄₀)-CO-N(R₄₁)-;

L₁₃ is hydrogen, alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl, or -alkylene-aryl;

L₁₁ is hydrogen, alkyl, alkenyl, alkynyl, -alkylene-aryl, -alkylene-heteroaryl, alkylene-O-alkylene-aryl, -alkylene-S-alkylene-aryl, -alkylene-O-alkyl, -alkylene-S-alkyl, -alkylene-NH₂, -alkylene-OH, -alkylene-SH, -alkylene-C(O)-OR₄₂, -alkylene-C(O)-NR₄₂R₄₃, -alkylene-NR₄₂R₄₃, -alkylene-N(R₄₂)-C(O)-R₄₃, , -alkylene-N(R₄₂)-S(O₂)-R₄₃, or the side chain of a natural or non-natural amino acid;

R₄₂ and R₄₃ are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-aryl;


wherein

R₄₂ and R₄₃ may be taken together to form a ring having the formula -(CH₂)_q-Y-(CH₂)_r- bonded to the nitrogen atom to which R₁₁ and R₁₂ are attached, wherein q and r are, independently, 1, 2, 3, or 4; Y is -CH₂-, -C(O)-, -O-, -N(H)-, -S-, -S(O)-, -SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -(O)CO-, -NHSO₂NH-, -OC(O)-, -N(R₄₄)-, -N(C(O)R₄₄)-, -N(C(O)NHR₄₄)-, -N(SO₂NHR₄₄)-, -N(SO₂R₄₄)-, or -N(C(O)OR₄₄)-; or

R₄₂ and R₄₃ may be taken together, with the nitrogen atom to which they are attached, to form a heterocyclcyl or heteroaryl ring;
R₄₀, R₄₁, and R₄₄ are independently selected from the group consisting of: hydrogen, aryl, alkyl, or alkylene-aryl;

and wherein

R₇ and R₈ are independently selected from the group consisting of hydrogen, -alkyl, -L₃-E-aryl, -C(O)-alkyl, -C(O)-



aryl, -SO₂-alkyl, -SO₂-aryl, and ;
wherein

R₉, R₁₀, and R₁₁ are independently selected from the group consisting of : -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

L₃ is a direct bond, -alkylene, -alkenylene, or -alkynylene;

E is a direct bond, -CH₂-, -O-, -N(R₁₂)-, -C(O)-, -CON(R₁₂)-, -N(R₁₂)C(O)-, -N(R₁₂)CON(R₁₃)-, -N(R₁₂)C(O)O-, -OC(O)N(R₁₂)-, -N(R₁₂)SO₂-, -SO₂N(R₁₂)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O₂)-, -N(R₁₂)SO₂N(R₁₃)-, -N=N-, or -N(R₁₂)-N(R₁₃)-,

wherein

R₁₂ and R₁₃ are independently selected from the group consisting of : -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

A is hydrogen, -alkyl, -alkenyl, or -alkynyl;

X is

- a) -C(O)-;

R₁ is

- a) -hydrogen;
- b) -fluoro
- c) -chloro
- d) -bromo
- e) -iodo
- f) -cyano
- g) -alkyl;
- h) -aryl;
- i) -alkylene-aryl;
- j) -heteroaryl;
- k) -alkylkene-heteroaryl;
- l) -cycloalkyl;
- m) -alkylene-cycloalkyl
- n) - heterocyclyl; or
- o) - alkylene-heterocyclyl;

R₂ is

- a) -perfluoroalkyl;
- b) -J-R₁₄;
- c) -alkyl;
- d) -aryl;
- e) -heteroaryl;
- f) -heterocyclyl;
- g) -cycloalkyl;
- h) -L₄ -aryl;
- i) -L₄-arylene-aryl;
- j) -L₄-arylene-alkyl;

- k) -arylene-alkyl;
- l) -arylene-arylene-alkyl;
- m) -J-alkyl;
- n) -J-aryl;
- o) -J-alkylene-aryl;
- p) -J-arylene-alkyl;
- q) -J-alkylene-arylene-aryl;
- r) -J-arylene-arylene-aryl;
- s) -J-alkylene-arylene-alkyl;
- t) -L₄-J-alkylene-aryl;
- u) -arylene-J-alkyl;
- v) -L₄-J-aryl;
- w) -L₄-J-heteroaryl;
- x) -L₄-J-cycloalkyl;
- y) -L₄-J-cycloalkylene-alkyl;
- z) -L₄-J-heterocyclyl;
- aa) -L₄-J-arylene-alkyl;
- bb) -L₄-J-alkylene-arylene-alkyl;
- cc) -L₄-J-alkyl;
- dd) -L₄-J-R₁₄;
- ee) -L₄-J-alkylene-R₁₄;
- ff) -J-L₄-R₁₄;
- gg) -arylene-J-R₁₄;
- hh) -L₄-arylene-J-alkyl;
- ii) -L₄-alkylene-J-alkyl;
- jj) -L₄-arylene-J-aryl; or
- kk) -hydrogen;

wherein


L₄ is a direct bond, -alkylene, -alkenylene, -alkynylene, heterocyclylene, cycloalkylene, arylene, or heteroarylene;

J is a direct bond, $-\text{CH}_2-$, $-\text{O}-$, $-\text{N}(\text{R}_{15})-$, $-\text{C}(\text{O})-$, $-\text{CON}(\text{R}_{15})-$, $-\text{N}(\text{R}_{15})\text{C}(\text{O})-$, $-\text{N}(\text{R}_{15})\text{CON}(\text{R}_{16})-$, $-\text{N}(\text{R}_{15})\text{C}(\text{O})\text{O}-$, $-\text{OC}(\text{O})\text{N}(\text{R}_{15})-$, $-\text{N}(\text{R}_{15})\text{SO}_2-$, $-\text{SO}_2\text{N}(\text{R}_{15})-$, $-\text{C}(\text{O})\text{O}-$, $-\text{O}-\text{C}(\text{O})-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O}_2)-$, $-\text{N}(\text{R}_{15})\text{SO}_2\text{N}(\text{R}_{16})-$, $-\text{N}=\text{N}-$, or $-\text{N}(\text{R}_{15})-\text{N}(\text{R}_{16})-$,

wherein

R_{15} and R_{16} are independently selected from the group consisting of :
 $-\text{hydrogen}$, $-\text{alkyl}$, $-\text{aryl}$, $-\text{arylene-alkyl}$, $-\text{alkylene-aryl}$, and
 $-\text{alkylene-arylene-alkyl}$,

R_{14} is: $-\text{hydrogen}$, $-\text{alkyl}$, $-\text{aryl}$, $-\text{arylene-alkyl}$, $-\text{alkylene-aryl}$, $-\text{alkylene-arylene-alkyl}$, or



wherein

L_{14} is $-\text{alkylene}$, $-\text{cycloalkylene}$, $-\text{heteroarylene}$, $-\text{arylene}$, or $-\text{heterocyclylene}$;

L_{16} is $-\text{O}-$, $-\text{C}(\text{O})-\text{N}(\text{R}_{45})-$, $-\text{C}(\text{O})\text{O}-$, $-\text{C}(\text{O})-$, or $-\text{N}(\text{R}_{45})-\text{CO}-\text{N}(\text{R}_{46})-$;

L_{17} is $-\text{hydrogen}$, $-\text{alkyl}$, $-\text{alkenyl}$, $-\text{alkynyl}$, $-\text{heterocyclyl}$, $-\text{heteroaryl}$, or $-\text{alkylene-aryl}$;

L_{15} is $-\text{hydrogen}$, $-\text{alkyl}$, $-\text{alkenyl}$, $-\text{alkynyl}$, $-\text{alkylene-aryl}$, $-\text{alkylene-heteroaryl}$, $-\text{alkylene-O-alkylene-aryl}$, $-\text{alkylene-S-alkylene-aryl}$, $-\text{alkylene-O-alkyl}$, $-\text{alkylene-S-alkyl}$, $-\text{alkylene-NH}_2$, $-\text{alkylene-OH}$, $-\text{alkylene-SH}$, $-\text{alkylene-C}(\text{O})-\text{OR}_{47}$, $-\text{alkylene-C}(\text{O})-\text{NR}_{47}\text{R}_{48}$, $-\text{alkylene-NR}_{47}\text{R}_{48}$, $-\text{alkylene-N}(\text{R}_{47})-\text{C}(\text{O})-\text{R}_{48}$, $-\text{alkylene-N}(\text{R}_{47})-\text{S}(\text{O}_2)-\text{R}_{48}$, or the side chain of a natural or non-natural amino acid;

R_{47} and R_{48} are independently selected from the group consisting of $-\text{hydrogen}$, $-\text{aryl}$, $-\text{alkyl}$, and $-\text{alkylene-aryl}$;

R₄₇ and R₄₈ may be taken together, with the nitrogen atom to which they are attached, to form a heterocyclyl or heteroaryl ring, R₄₅ and R₄₆ are independently selected from the group consisting of hydrogen, aryl, alkyl, and alkylene-aryl;

R₃ is

- a) -hydrogen
- b) -alkyl
- c) -aryl;
- d) -alkylene-cycloalkyl;
- e) -arylene-alkyl;
- f) -alkylene-aryl; or
- g) -alkylene-heteroaryl;

Ar₁ is an aryl or fused cycloalkylaryl group optionally substituted 1 to 7 times and if Ar₁ is phenyl, the phenyl has 1 to 5 substituents, wherein the substituents for Ar₁ are selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -alkyl;
- i) -aryl;
- j) -heteroaryl;
- k) -heterocyclyl;
- l) -cycloalkyl;
- m) -L₅-aryl;

- n) - L₅-arylene-aryl;
- o) - L₅-arylene-alkyl;
- p) -arylene-alkyl;
- q) -arylene-arylene-alkyl;
- r) -K-alkyl;
- s) -K-aryl;
- t) -K-alkylene-aryl;
- u) -K-arylene-alkyl;
- v) -K-alkylene-arylene-aryl;
- w) -K-arylene-arylene-aryl;
- x) -K-alkylene-arylene-alkyl;
- y) - L₅-K-alkylene-aryl;
- z) -arylene-K-alkyl;
- aa) - L₅-K-aryl;
- bb) - L₅-K-heteroaryl;
- cc) - L₅-K-cycloalkyl;
- dd) - L₅-K-heterocyclyl;
- ee) - L₅-K-arylene-alkyl;
- ff) - L₅-K-alkylene-arylene-alkyl;
- gg) - L₅-K-alkyl; and
- hh) -arylene-K-R₁₇;

wherein

L₅ is a direct bond, -alkylene, -alkenylene, or -alkynylene;

K is a direct bond, -CH₂-, -N(R₁₈)-, -C(O)-, -CON(R₁₈)-, -N(R₁₈)C(O)-, -N(R₁₈)CON(R₁₉)-, -N(R₁₈)C(O)O-, -OC(O)N(R₁₈)-, -N(R₁₈)SO₂-, -SO₂N(R₁₈)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O₂)-, -N(R₁₈)SO₂N(R₁₉)-, -N=N-, or -N(R₁₈)-N(R₁₉)-,

wherein

R₁₇, R₁₈, and R₁₉ are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

Ar₂ is an arylene, fused arylcycloalkylene, or fused cycloalkylarylene group optionally substituted 1 to 7 times;

L₁ is a direct bond, ~~CH₂, O-, alkylene, alkenylene, -O-alkylene-, or -alkylene-O-,~~
~~N(R₂₃), C(O), CON(R₂₃), N(R₂₃)C(O), N(R₂₃)CON(R₂₄), N(R₂₃)C(O)O,~~
~~OC(O)N(R₂₃), N(R₂₃)SO₂, SO₂N(R₂₃), C(O)O, O C(O), S, S(O), S(O₂),~~
~~N(R₂₃)SO₂N(R₂₄), N=N, or N(R₂₃)N(R₂₄);~~

wherein

R₂₃ and R₂₄ are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, alkylene-aryl, -alkylene-arylene-alkyl, and a direct bond;

T is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, or fused heterocyclylheteroaryl group optionally substituted 1 to 7 times, wherein the substituents are independently selected from the group consisting of:


- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -U-R₂₅;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L₇ -aryl;

- o) -L₇-arylene-aryl;
- p) -L₇-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -U-alkyl;
- t) -U-aryl;
- u) -U-alkylene-aryl;
- v) -U-arylene-alkyl;
- w) -U-alkylene-arylene-aryl;
- x) -U-arylene-arylene-aryl;
- y) -U-alkylene-arylene-alkyl;
- z) -L₇-U-alkylene-aryl;
- aa) -arylene-U-alkyl;
- bb) -L₇-U-aryl;
- cc) -L₇-U-heteroaryl;
- dd) -L₇-U-cycloalkyl;
- ee) -L₇-U-heterocyclyl;
- ff) -L₇-U-arylene-alkyl;
- gg) -L₇-U-alkylene-arylene-alkyl;
- hh) -L₇-U-alkyl;
- ii) -L₇-U-alkylene-aryl-R₂₅;
- jj) -L₇-U-alkylene-heteroaryl- R₂₅;
- kk) -arylene-U-alkylene- R₂₅;
- ll) -heteroarylene-U-alkylene- R₂₅;
- mm) -L₇-U-aryl- R₂₅;
- nn) -L₇-U-heteroarylene- R₂₅;
- oo) -L₇-U-heteroaryl- R₂₅;
- pp) -L₇-U-cycloalkyl- R₂₅;
- qq) -L₇-U-heterocyclyl- R₂₅;
- rr) -L₇-U-arylene-alkyl- R₂₅;
- ss) -L₇-U-heteroarylene-alkyl- R₂₅;

U is a direct bond, $-\text{CH}_2-$, $-\text{O}-$, $-\text{N}(\text{R}_{26})-$, $-\text{C}(\text{O})-$, $-\text{CON}(\text{R}_{26})-$, $-\text{N}(\text{R}_{26})\text{C}(\text{O})-$, $-\text{N}(\text{R}_{26})\text{CON}(\text{R}_{27})-$, $-\text{N}(\text{R}_{26})\text{C}(\text{O})\text{O}-$, $-\text{OC}(\text{O})\text{N}(\text{R}_{26})-$, $-\text{N}(\text{R}_{26})\text{SO}_2-$, $-\text{SO}_2\text{N}(\text{R}_{26})-$, $-\text{C}(\text{O})-\text{O}-$, $-\text{O}-\text{C}(\text{O})-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O}_2)-$, $-\text{N}(\text{R}_{26})\text{SO}_2\text{N}(\text{R}_{27})-$, $\text{N}=\text{N}-$, or $-\text{N}(\text{R}_{26})-\text{N}(\text{R}_{27})-$;

wherein

R_{26} and R_{27} are independently selected from the group consisting of : -
hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and
-alkylene-arylene-alkyl;



Y_2 is hydrogen, $-\text{CO}_2\text{H}$, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;
 R_{25} is $-\text{SO}_3\text{H}$, $-\text{P}(\text{O})(\text{OH})_2$, $-\text{P}(\text{O})(\text{O-alkyl})(\text{OH})$, $-\text{CO}_2\text{H}$, $-\text{CO}_2$ -alkyl, an acid isostere, -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl,

or a pharmaceutically acceptable salt or solvate thereof.

2. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein W is $-\text{N}(\text{R}_4)-$, wherein R_4 is -alkyl, $-\text{L}_2$ -D-alkyl, or $-\text{L}_2$ -D-aryl, wherein L_2 is alkylene, and D is a direct bond, $-\text{C}(\text{O})-$ or $-\text{O}-$.

3. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein W is $-\text{N}(\text{R}_4)-$, wherein R_4 is hydrogen.

4. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein W is $-\text{N}(\text{R}_4)-$, wherein R_4 is $-\text{L}_2$ -D-G, wherein L_2 is alkenyl or alkynyl, D is a direct bond, and G is hydrogen or alkyl.

5. (Canceled).
6. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R₁ is hydrogen or aryl.
7. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R₂ is: -alkyl, -aryl, -L₄-J-cycloalkyl, arylene-alkyl, -L₄-arylene-J-alkyl, or -J-alkyl, wherein L₄ is alkylene or alkenylene, and J is a direct bond or -O-.
8. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R₃ is -H; X is -C(O)-; R₂ is -L₄-arylene-J-alkyl, -L₄-J-cycloalkylene-alkyl or -L₄-J-alkylene-aryl, wherein L₄ is alkylene, alkenylene, or a direct bond; and J is a direct bond, -O-, or -NH-.
9. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R₃ is hydrogen.
10. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar₁ is a phenyl or naphthyl group having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:
- a) -fluoro;
 - b) -chloro;
 - c) -bromo;
 - d) -iodo;
 - e) -cyano;
 - f) -nitro;
 - g) -perfluoroalkyl;
 - h) -alkyl;

- i) -aryl;
- j) -heteroaryl;
- k) -heterocyclyl;
- l) -cycloalkyl;
- m) -L₅-aryl;
- n) -L₅-arylene-aryl;
- o) -L₅-arylene-alkyl;
- p) -arylene-alkyl;
- q) -arylene-arylene-alkyl;
- r) -K-alkyl;
- s) -K-aryl;
- t) -K-alkylene-aryl;
- u) -K-arylene-alkyl;
- v) -K-alkylene-arylene-aryl;
- w) -K-arylene-arylene-aryl;
- x) -K-alkylene-arylene-alkyl;
- y) -L₅-K-alkylene-aryl;
- z) -arylene-K-alkyl;
- aa) -L₅-K-aryl;
- bb) -L₅-K-heteroaryl;
- cc) -L₅-K-cycloalkyl;
- dd) -L₅-K-heterocyclyl;
- ee) -L₅-K-arylene-alkyl;
- ff) -L₅-K-alkylene-arylene-alkyl;
- gg) -L₅-K-alkyl;
- and
- hh) -arylene-K-R₁₇;

wherein

L₅ is a direct bond, -alkylene, -alkenylene, or -alkynylene;

K is a direct bond, -CH₂-, -N(R₁₈)-, -C(O)-, -CON(R₁₈)-, -N(R₁₈)C(O)-, -N(R₁₈)CON(R₁₉)-, -N(R₁₈)C(O)O-, -OC(O)N(R₁₈)-, -N(R₁₈)SO₂-, -

SO₂N(R₁₈)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O₂)-, -N(R₁₈)SO₂N(R₁₉)-, -N=N-, or -N(R₁₈)-N(R₁₉)- ,

wherein

R₁₇, R₁₈, and R₁₉ are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl.

11. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar₁ is a phenyl group substituted 1 to 5 times with substituents independently selected from the group consisting of:



- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo; and
- e) -nitro.

12. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar₂ is a phenylene or naphthylene group optionally having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -Q-R₂₀;
- i) -alkyl;
- j) -aryl;

- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L₆-aryl;
- o) -L₆-arylene-aryl;
- p) -L₆-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -Q-alkyl;
- t) -Q-aryl;
- u) -Q-alkylene-aryl;
- v) -Q-arylene-alkyl;
- w) -Q-alkylene-arylene-aryl;
- x) -Q-arylene-arylene-aryl;
- y) -Q-alkylene-arylene-alkyl;
- z) -L₆-Q-alkylene-aryl;
- aa) -arylene-Q-alkyl;
- bb) -L₆-Q-aryl;
- cc) -L₆-Q-heteroaryl;
- dd) -L₆-Q-cycloalkyl;
- ee) -L₆-Q-heterocyclyl;
- ff) -L₆-Q-arylene-alkyl;
- gg) -L₆-Q-alkylene-arylene-alkyl;
- hh) -L₆-Q-alkyl;
- ii) -L₆-Q-alkylene-aryl-R₂₀;
- jj) -L₆-Q-alkylene-heteroaryl-R₂₀;
- kk) -arylene-Q-alkylene- R₂₀;
- ll) -heteroarylene-Q-alkylene- R₂₀;
- mm) -L₆-Q-aryl- R₂₀;
- nn) -L₆-Q-heteroarylene- R₂₀;
- oo) -L₆-Q-heteroaryl- R₂₀;

pp) -L₆-Q-cycloalkyl- R₂₀;
 qq) -L₆-Q-heterocyclyl- R₂₀;
 rr) -L₆-Q-arylene-alkyl- R₂₀;
 ss) -L₆-Q-heteroarylene-alkyl- R₂₀;
 tt) -L₆-Q-alkylene-arylene-alkyl- R₂₀;
 uu) -L₆-Q-alkylene-heteroarylene-alkyl- R₂₀;
 vv) -L₆-Q-alkylene-cycloalkylene-alkyl- R₂₀;
 ww) -L₆-Q-alkylene-heterocyclylene-alkyl- R₂₀;
 xx) -L₆-Q-alkyl- R₂₀;
 yy) -L₆-Q- R₂₀;
 zz) -arylene-Q- R₂₀;
 aaa) -heteroarylene-Q- R₂₀;
 bbb) -heterocyclylene-Q- R₁₈;
 ccc) -Q-alkylene- R₂₀;
 ddd) -Q-arylene- R₂₀;
 eee) -Q-heteroarylene- R₂₀;
 fff) -Q-alkylene-arylene- R₂₀;
 ggg) -Q-alkylene-heteroarylene- R₂₀;
 hhh) -Q-heteroarylene-alkylene- R₂₀;
 iii) -Q-arylene-alkylene- R₂₀;
 jjj) -Q-cycloalkylene-alkylene- R₂₀;
 kkk) -Q-heterocyclylene-alkylene- R₂₀;
 lll) -Q-alkylene-arylene-alkyl- R₂₀; or
 mmm) -Q-alkylene-heteroarylene-alkyl- R₂₀;



ppp) -hydrogen,


wherein

L_6 is a direct bond, -alkylene, -alkenylene, or -alkynylene;

Q is a direct bond, $-\text{CH}_2-$, $-\text{O}-$, $-\text{N}(\text{R}_{21})-$, $-\text{C}(\text{O})-$, $-\text{CON}(\text{R}_{21})-$, $-\text{N}(\text{R}_{21})\text{C}(\text{O})-$, $-\text{N}(\text{R}_{21})\text{CON}(\text{R}_{22})-$, $-\text{N}(\text{R}_{21})\text{C}(\text{O})\text{O}-$, $-\text{OC}(\text{O})\text{N}(\text{R}_{21})-$, $-\text{N}(\text{R}_{21})\text{SO}_2-$, $-\text{SO}_2\text{N}(\text{R}_{21})-$, $-\text{C}(\text{O})\text{O}-$, $-\text{O}-\text{C}(\text{O})-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O}_2)-$, $-\text{N}(\text{R}_{21})\text{SO}_2\text{N}(\text{R}_{22})-$, $\text{N}=\text{N}-$, or $-\text{N}(\text{R}_{21})-\text{N}(\text{R}_{22})-$;

wherein

R_{21} and R_{22} are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;



Z is hydrogen, $-\text{CO}_2\text{H}$, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R_{20} is $-\text{SO}_3\text{H}$, $-\text{P}(\text{O})(\text{OH})_2$, $-\text{P}(\text{O})(\text{O-alkyl})(\text{OH})$, $-\text{CO}_2\text{H}$, $-\text{CO}_2$ -alkyl, an acid isostere, hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

13. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_2 is a phenylene or naphthylene group optionally substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) $-\text{Q}-\text{R}_{20}$;
- f) -alkyl;
- g) -aryl;
- h) -arylene-alkyl;

- i) -Q-alkyl; and
- j) -arylene-Q-alkyl;

wherein

Q is: $-\text{CH}_2-$, $-\text{O}-$, $-\text{C}(\text{O})-$, or $-\text{C}(\text{O})-\text{O}-$; and

R_{20} is: -hydrogen, -alkyl, -aryl, cycloalkyl, -alkenyl, $-\text{CO}_2\text{H}$, or an acid isostere.

14. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_2 is a phenylene group substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -Q- R_{20} ;
- f) -alkyl;
- g) -phenyl;
- h) -phenylene-alkyl;
- i) -Q-alkyl; and
- j) -phenylene-Q-alkyl;

wherein


Q is: $-\text{CH}_2-$, $-\text{O}-$, $-\text{C}(\text{O})-$, or $-\text{C}(\text{O})-\text{O}-$; and

R_{20} is: -hydrogen, -alkyl, -phenyl, -cycloalkyl, alkenyl, or $-\text{CO}_2\text{H}$.

15. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_2 is a phenylene group substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of :

- a) -Q-alkyl;
- b) -Q-arylene- R_{20} ;

c) -Q-alkylene-arylene-R₂₀; and



d) -Q-

wherein

Q is: -CH₂-, -O-, -C(O)-, or -C(O)-O-;

Z is -CO₂H or an acid isostere;



V is ; and

R₂₀ is: -CO₂H or an acid isostere.

16. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein L₁ is -O-alkylene-~~or a~~ direct bond.

17. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein T is an aryl group substituted by -U-alkylene-R₂₅, wherein U is -O- or a direct bond and R₂₅ is -CO₂H or an acid isostere.

18. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein X and R₂ together form a group selected from the group consisting of:

tert-butoxycarbonyl, tert-butyl-methyl-carbonyl, 4-cyclohexyl-butyryl, 3-cyclohexyl-propionyl, 2-cyclohexyl-acetyl, 4-tert-butyl-phenyl)-carbonyl, 4-(4'-methoxyphenyl)-butyryl, 4-(4'-methoxyphenyl)-butyryl, 3-(4'-methoxyphenyl)-propionyl, 3-(3'-methoxyphenyl)-propionyl, 3-(4'-methoxy-phenyl)-acryl, 3-(4'-chloro-phenyl)-acryl, 2-(4'-methoxy-phenyl)-acetyl, 2-(4'-chloro-phenyl)-acetyl, 2-(4'-methylsulfonyl-phenyl)-acetyl, 2-(4'-methylsulfonyl-phenyl)-acetyl, 4-(4'-

chloro-2'-methyl-phenoxy)-butyryl, 4-(4'-methoxyphenyl)-butyryl, and 4-(4'-cyclohexyl)-propyl.

19. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein a equals 0, and the groups T, L₁, and Ar₂ together form a group selected from the group consisting of: 4'-n-butoxy-3'-n-butoxy carbonyl phenyl, and 4'-n-butoxy-3'-carboxyl phenyl.

20. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar₁ is selected from the group consisting of naphthyl, 4-nitrophenyl, 4-chlorophenyl, 3-chlorophenyl, 3, 4-dichlorophenyl, 2, 4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 4-cyanophenyl, 4-bromophenyl, and pentafluorophenyl.

21. (Currently Amended) The compound of Formula (I) according to claim 1, where the compound of Formula (I) is selected from the group consisting of:

- 2-[3-(4'-Methoxyphenyl)-propionylamino]-2-(4'-n-butoxy-3'-carboxyphenyl)-2-ethyl[4-(4'-nitrophenyl)]imidazole;
- 2-[3-(4'-Methoxy-phenyl)-acrylamino]-2-(4'-n-butoxy-3'-carboxyphenyl)-2-ethyl[4-(4'-nitrophenyl)]imidazole;
- 2-[4-(4'-Methoxyphenyl)-butyryl amino]-2-(4'-n-butoxy-3'-carboxy phenyl)-2-ethyl [4-(2', 4'-dichlorophenyl)] imidazole;
- 2-[4-(4'-Cyclohexyl)-propanoylamino]-2-(4'-n-butoxy-3'-carboxyphenyl)-2-ethyl[4-(2', 4'-dichlorophenyl)] imidazole;
- N-[(1*S*)-2-(4-(1,1-Dicarboxymethoxy)phenyl)-1-[4-(2,4-dichlorophenyl)-1*H*-1-(1-butyl)imidazol-2-yl]ethyl]-4-tert-butylcyclohexanecarboxamide;
- 4-(4-{(2*S*)-2-[(4-tert-Butyl-cyclohexanecarbonyl)-amino]-2-[1-butyl-4-(2,4-dichloro-phenyl)-1*H*-imidazol-2-yl]-ethyl}-phenoxymethyl)-benzoic acid;
- 4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1*H*-imidazol-2-yl]- (2*S*)-2-[2-(4-methoxy-phenyl)-acetylaminol-ethyl]-phenoxymethyl)-benzoic acid;
- 4-{4-[2-[1-Butyl-4-(2,4-dichloro-phenyl)-1*H*-imidazol-2-yl]- (2*S*)-2-(2-cyclopentyl-acetylaminol-ethyl)-phenoxymethyl]-benzoic acid;
- 4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1*H*-imidazol-2-yl]- (2*S*)-2-[(*trans*-4-methyl-cyclohexanecarbonyl)-amino]-ethyl]-phenoxymethyl)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[(*trans*-4-ethyl-cyclohexanecarbonyl)-amino]-ethyl}-phenoxy)methyl)-benzoic acid;

4-(4-{(2S)-2-[(4-*tert*-Butyl-cyclohexanecarbonyl)-amino]-2-[4-(2,4-dichloro-phenyl)-(*E*)-1-pent-2-enyl-1H-imidazol-2-yl]-ethyl}-phenoxy)methyl)-benzoic acid;

4-(4-{2-[4-(2,4-Dichloro-phenyl)-(*E*)-1-pent-2-enyl-1H-imidazol-2-yl]- (2S)-2-[(*trans*-4-ethyl-cyclohexanecarbonyl)-amino]-ethyl}-phenoxy)methyl)-benzoic acid;

4-(4-{2-[1-But-2-ynyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[(*trans*-4-ethyl-cyclohexanecarbonyl)-amino]-ethyl}-phenoxy)methyl)-benzoic acid;

4-(4-{(2S)-2-[(4-*tert*-Butyl-cyclohexanecarbonyl)-amino]-2-[1-butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[(*trans*-4-ethyl-cyclohexane-carbonyl)-amino]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[4-(2,4-Dichloro-phenyl)-1-pent-2-enyl-1H-imidazol-2-yl]- (2S)-2-[(*trans*-4-ethyl-cyclohexane-carbonyl)-amino]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-But-2-ynyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[(*trans*-4-ethyl-cyclohexanecarbonyl)-amino]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[4-(3-fluorobenzylcarbamoyl)-butyrylamino]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[2-(4-methoxy-phenyl)-acetylamino]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[2-(2,4-difluorophenyl)-acetylamino]-ethyl}-phenoxy)-benzoic acid;

4-(4-[2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-(4-methoxy-benzoylamino)-ethyl]-phenoxy)-benzoic acid;

4-(4-[2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-(3,5-difluoro-benzoylamino)-ethyl]-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[3-(2,4-difluoro-phenyl)-ureido]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[3-(4-methoxy-phenyl)-ureido]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[3-(3-methoxy-phenyl)-ureido]-ethyl}-phenoxy)-benzoic acid;

4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[3-(4-trifluoromethyl-phenyl)-2-(2S)-isobutyrylamino-propionylamino]-ethyl}-phenoxy)-benzoic acid;

- 4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[3-(4-tert-butyl-phenyl)-(2S)-2-isobutrylamino-propionylamino]-ethyl}-phenoxy)-benzoic acid; and
- 4-(4-{2-[1-Butyl-4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]- (2S)-2-[4-(4-chloro-phenyl)-(3S)-3-isobutrylamino-butrylamino]-ethyl}-phenoxy)-benzoic acid;
- or pharmaceutically acceptable salts or solvates thereof.

22. (Previously Presented) A pharmaceutically composition comprising a compound as claimed in claim 1.
23. (Previously Presented) The pharmaceutical composition of claim 22, wherein said compound is a topical formulation.
24. (Previously Presented) The pharmaceutical composition of claim 23, wherein the pharmaceutical composition is suitable for administration of said compound in a formulation ratio of 0.1% to 99% of compound to topical excipient.
25. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1 sufficient to inhibit protein tyrosine phosphatase.
26. (Original) The pharmaceutical composition of claim 25, in the form of an oral dosage or parenteral dosage unit.
27. (Previously Presented) The pharmaceutical composition of claim 25, wherein the pharmaceutical composition is suitable for administration of said compound as a dose in a range from about 0.003 to 500 mg/kg of body weight per day.
28. (Previously Presented) The pharmaceutical composition of claim 25, wherein the pharmaceutical composition is suitable for administration of said compound as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.

29. (Previously Presented) The pharmaceutical composition of claim 25, wherein the pharmaceutical composition is suitable for administration of said compound as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.

30. (Original) The pharmaceutical composition of claim 25, further comprising one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, acarbose, PPAR agonists, DPP-IV inhibitors, GK activators, insulin, insulin mimetics, insulin secretagogues, insulin sensitizers, GLP-1, GLP-1 mimetics, cholinesterase inhibitors, antipsychotics, antidepressants, anticonvulsants, HMG CoA reductase inhibitors, cholestyramine, and fibrates.

31. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type I diabetes.

32. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type II diabetes.

33-35. (canceled).

36. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat glucose intolerance.

37. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat obesity.

38. (canceled).

39. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat psoriasis.

40-62. (canceled).

63. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 2.

64. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 3.

65. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 4.

66. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 6.

67. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 7.

68. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 8.

69. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 9.

70. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 10.

71. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 11.

72. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 12.

73. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 13.

74. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 14.

75. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 15.

76. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 16.

77. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 17.

78. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 18.

79. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 19.

80. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 20.

81. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 21.